Australia markets close in 1 hour 52 minutes

Neovasc Inc. (NVCN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
29.71+0.35 (+1.19%)
At close: 04:00PM EDT
29.41 -0.30 (-1.01%)
After hours: 05:08PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close29.36
Bid29.41 x 800
Ask29.75 x 800
Day's range29.28 - 29.75
52-week range4.59 - 29.88
Avg. volume63,218
Market cap82.372M
Beta (5Y monthly)2.01
PE ratio (TTM)N/A
EPS (TTM)-12.40
Earnings date10 May 2023 - 15 May 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est24.00
  • Simply Wall St.

    Neovasc's (TSE:NVCN) investors will be pleased with their solid 171% return over the last year

    The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. On the other hand, if you...

  • GlobeNewswire

    Neovasc Shareholders Approve Acquisition by Shockwave Medical

    VANCOUVER, BC, March 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the “Shares”) by Shockwave Medical, Inc. (“Shockwave”) by way of a statutory plan of arrangem

  • GlobeNewswire

    Neovasc Announces German Reimbursement Renewal

    VANCOUVER and MINNEAPOLIS, Feb. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc, Inc. (“Neovasc” or “the Company”) (NASDAQ , TSX : NVCN) today announced the German Institute for the Hospital Remuneration System (“InEK”) has awarded the Neovasc Reducer™ (“Reducer”), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation for 2023. New examination and treatment methods (NUBs) are comprised of novel and innovative medicines, medical products and procedure